Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
49.83
+0.89 (1.82%)
Apr 22, 2025, 12:15 PM EDT - Market open
BMY Revenue
In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth. Bristol-Myers Squibb Company had revenue of $12.34B in the quarter ending December 31, 2024, with 7.54% growth.
Revenue (ttm)
$48.30B
Revenue Growth
+7.32%
P/S Ratio
2.05
Revenue / Employee
n/a
Employees
n/a
Market Cap
101.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
BMY News
- 5 hours ago - Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession - Seeking Alpha
- 1 day ago - LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed - FXEmpire
- 1 day ago - Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
- 4 days ago - U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications - Business Wire
- 5 days ago - 2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT - Business Wire
- 6 days ago - Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday? - Benzinga
- 7 days ago - Bristol Myers' heart disease drug fails to meet main goals in late-stage study - Reuters
- 7 days ago - Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial - Business Wire